Trending: AstraZeneca Gets Green Light for Cancer Treatment in US
0947 GMT - AstraZeneca is among the most mentioned companies across news items over the past six hours, according to Factiva data. The Anglo-Swedish company said the U.S. drug regulator approved its drug Lynparza as a prostate cancer treatment, and also that it has decided to discontinue the development of another drug for inflammatory bowel disease. Lynparza was approved for the treatment of metastatic castration-resistant prostate cancer after success in a phase-3 trial. The treatment will be administered in combination with abiraterone and prednisone, the company said. Separately, AstraZeneca said it has discontinued the development of monoclonal antibody brazikumab for the treatment of inflammatory bowel disease, citing the competitive landscape in drug development. Dow Jones & Co. owns Factiva. (cecilia.butini@wsj.com)
(END) Dow Jones Newswires
June 01, 2023 06:02 ET (10:02 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.-
Will Earnings From These 10 AI Stocks Live Up to the Hype?
-
What’s Happening In the Markets This Week
-
What the Next Bitcoin Halving Means for ETF Investors
-
Going Into Earnings, Is Microsoft a Buy, a Sell, or Fairly Valued?
-
Big Banks: High Interest Rates and Sticky Inflation Haven’t Dented Consumer Spending
-
Is the World Deglobalizing?
-
How to Position Your Investment Portfolio Before the 2024 Election
-
Q2 Update: 2024 Outlook for the Stock Market and Economy
-
Regions Financial Earnings: Mixed Quarter, 2024 Outlook Mostly Reiterated
-
Going Into Earnings, Is Amazon Stock a Buy, a Sell, or Fairly Valued?
-
Fifth Third Earnings: Mostly Solid Start to 2024
-
Israel’s Response to Iran’s Strike Confirms Minimal Escalation View; Oil Markets Remain Oversupplied
-
Procter & Gamble Earnings: Muted Sales Growth Doesn’t Reflect a Stained Brand Mix
-
TSMC Earnings: Shares Cheap as Cautious Capital Spending and Industry Outlook Dent Sentiment
-
Netflix Earnings: Incredible Quarter, but Investors Fear Slowdown
-
KeyCorp Earnings: 2024 Net Interest Income Outlook Unchanged; Fees Strong and Expenses Stable